Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Related MRK
Merck Announces That IMPROVE-IT Achieved Primary Endpoint; Data To Be Presented At American Heart Association Scientific Sessions Today
Merck Announces Results From Phase 2 Study Of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir In Genotype 1 Infected Treatment-Naïve And Difficult-To-Cure Patients
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Latest Ratings for MRK

DateFirmActionFromTo
Nov 2014JefferiesMaintainsHold
Oct 2014JefferiesMaintainsHold
Oct 2014Guggenheim SecuritiesInitiates Coverage onNeutral

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: News Upgrades Price Target Markets Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional